Vytorin Managed Care Outlook More Positive Than Crestor, Survey Finds

Merck/Schering-Plough's Vytorin is likely to have favorable formulary coverage with approximately 38% of managed care payors within the first year of launch, according to a survey by Prudential Equity Group